Skip to main content
. Author manuscript; available in PMC: 2019 May 2.
Published in final edited form as: Leukemia. 2018 Oct 5;33(3):638–652. doi: 10.1038/s41375-018-0280-0

Figure 3. BM hematopoietic progenitor frequencies are diminished in CLL patients.

Figure 3.

(A-B) Freshly isolated ACK-lysed BM cells were stained with combinations of antibodies to distinguish specific progenitor frequencies of lineage-biased BM progenitors as a function of total CD19-excluded cells. (A) Monocyte and (B) Myelo-erythroid cell progenitors. HC n=25 and CLL n=15 (38 individual experiments). (C-F) Frequencies of specific progenitor frequencies were evaluated as a function of Lin-CD19- cells. (C) HSC, hematopoietic stem cell (D) MPP, multipotent progenitor, (E) CMP, common myeloid progenitor, and (F) CLP, common lymphocyte progenitor. HC n=37, CLL n=26 (57 individual experiments). (G) NK cell progenitors were assessed as a function of total CD19-excluded cells. HC n=28 and CLL n=19 (44 individual experiments). See Table S3 for phenotypic definitions for each population. Bars and error represents mean and SEM of each group whereas each point indicates individual subjects. Numbers under each figure represent the range for each parameter evaluated for HCs and CLL patients. **P<0.01, and ****P<0.0001 were obtained by Mann-Whitney U-test.